Processa Pharmaceuticals
PCSA
13 hedge funds and large institutions have $12.3M invested in Processa Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 2 closing their positions.
300% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 2
143% more capital invested
Capital invested by funds: $5.07M → $12.3M (+$7.22M)
86% more funds holding
Funds holding: 7 → 13 (+6)
0% more ownership
Funds ownership: 0.01% → 0.01% (+0%)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$3.61M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.2M |
| 3 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$848K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$261K |
| 5 |
CBA
Coastal Bridge Advisors
Westport,
Connecticut
|
+$186K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Solas Capital Management
Darien,
Connecticut
|
-$2.33M |
| 2 |
MA
MYDA Advisors
Woodmere,
New York
|
-$265K |
| 3 |
Millennium Management
New York
|
-$121K |
| 4 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
-$28K |
| 5 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$18.6K |
PCSA Hedge Fund Activity: Q1 2021 in Review
13 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Processa Pharmaceuticals (PCSA) for Q1 2021, worth a combined $12.3M — up 143% from $5.07M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new PCSA positions and 2 closed out — a net gain of 6 holders — while 1 added to existing stakes and 4 trimmed.
The largest buyer was AIGH Capital Management, opening a new position worth an estimated $3.61M. The largest seller was Solas Capital Management, cutting an estimated $2.33M.
- 13 institutional investors held Processa Pharmaceuticals (PCSA) as of Q1 2021, up from 7 in Q4 2020.
- Funds reported $12.3M of Processa Pharmaceuticals stock for Q1 2021, up 143% quarter-over-quarter.
- 8 funds opened new Processa Pharmaceuticals positions in Q1 2021 and 2 closed out, a net change of +6 holders.
- The largest Processa Pharmaceuticals buyer in Q1 2021 was AIGH Capital Management, an estimated $3.61M added.
- The largest Processa Pharmaceuticals seller in Q1 2021 was Solas Capital Management, an estimated $2.33M sold.
Based on aggregated 13F filings for Q1 2021.